LentiGlobin Gene Therapy Continues to Show Promising Results in SCD, Updated Trial Data Shows
Bluebird Bio’s LentiGlobin continues to show promising results in SCD patients participating in a Phase 1/2 HGB-206 clinical trial, new data shows. Read more here.
What did you think of this article?
Sorry, there were no replies found.
Log in to reply.